In a 48-week phase 2 trial published in The New England Journal of Medicine , adults with obesity (without type 2 diabetes) receiving once-weekly subcutaneous retatrutide at the 12 mg amount achieved a least-squares mean body weight reduction of 24.2%, compared with 2.1% in the placebo group [1]
GLP-1 receptor agonists should be considered when patients experience significant weight regain with BMI 27 kg/m with obesity-related comorbidities or BMI 30 kg/m, lifestyle modifications have been insufficient, no anatomical complications require surgical revision, and patients are willing to engage in long-term pharmacotherapy
If youre curious about taking a GLP-1 for PCOS, have a conversation with your doctor who can talk you through side effects , contraindications, and if its a good fit for your treatment plan, says Dr
With any new product that takes the world by storm in the way Raspberry Ketones have, it stands to reason that with demand comes supply
Pharmaceutical-grade retatrutide must be manufactured in FDA-inspected facilities with full traceability and cGMP compliance